What is the size of the Global Hepatocellular Carcinoma Market?

The Global Hepatocellular Carcinoma Market was valued at USD 1.85 billion and is projected to reach a market size of USD 3.21 billion by the end of 2030. Over the forecast period of 2023-2030, the market is projected to grow at a CAGR of 8.20%.

What are the Global Hepatocellular Carcinoma Market drivers?

There has been an increase in the Prevalence of Liver Cancer, Noval Drugs are getting approval.

What are the segments under the Hepatocellular Carcinoma Market by Treatment type?

Based on Treatment type, the Hepatocellular Carcinoma Market is segmented into Surgery, Radiation therapy, Chemotherapy, Immunotherapy and Targeted therapy.

Which is the most dominant region for the Global Hepatocellular Carcinoma Market?

North America is the most dominant region for the Global Hepatocellular Carcinoma Market.

Who are the leading players in the Global Hepatocellular Carcinoma Market?

Bayer AG, Bristol-Myers Squibb Company, Eisai Co., Ltd., Exelixis, Inc., F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Merck & Co., Inc., Novartis International AG, Onyx Pharmaceuticals, Inc., Pfizer Inc., Taiho Pharmaceutical Co., Ltd.